Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate

Abstract

This invention relates to wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate.

1 - 4 . (canceled) 
     
     
         5 . A topical pharmaceutical composition in sterile powder form, containing as active ingredient a combination of:
 a) glycine and proline; and   b) sodium hyaluronate.   
     
     
         6 . The topical pharmaceutical composition of  claim 5 , the composition further comprising as active ingredient:
 c) lysine and leucine.   
     
     
         7 . The topical pharmaceutical composition of  claim 5 , wherein proline is L-proline, and wherein glycine, L-proline and sodium hyaluronate are comprised within the following percentage ranges by weight:
 glycine 0.5 to 2%;   L-proline. 0.2 to 1.5%; and   sodium hyaluronate: 0.5 to 3%.   
     
     
         8 . The topical pharmaceutical composition of  claim 6 , wherein lysine is L-lysine, leucine is L-leucine and wherein L-lysine and L-leucine are comprised within the following percentage ranges by weight:
 L-lysine hydrochloride: 0.05 to 1%; and   L-leucine: 0.05 to 0.3%.   
     
     
         9 . The topical pharmaceutical composition of  claim 5 , wherein proline is L-proline, and wherein glycine, L-proline and sodium hyaluronate have the following percentage by weight:
 glycine 1%;   L-proline: 0.75%; and   sodium hyaluronate: 1.33%.   
     
     
         10 . The topical pharmaceutical composition of  claim 6 , wherein lysine is L-lysine, leucine is L-leucine and wherein L-lysine and L-leucine have the following percentage by weight:
 L-lysine hydrochloride: 0.1%; and   L-leucine: 0.15%.   
     
     
         11 . A method for treating a wound in a biological tissue, the method comprising 
       administering to the biological tissue a topical medicament in sterile powder, the topical medicament comprising a combination of
 a) glycine and proline; and 
 b) sodium hyaluronate. 
 
     
     
         12 . The method of  claim 11 , wherein the medicament further comprises
 c) lysine and leucine.   
     
     
         13 . The method of  claim 11 , wherein, the wound is a chronic ulcerous wound, a serious burn, a surgical wound, a chronic ulcerous wound, a serious burn or a surgical wound.